{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:05:44Z","timestamp":1769522744819,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["trasci.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.transci.2024.104053","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T18:52:23Z","timestamp":1734461543000},"page":"104053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Ruxolitinib in the management of chronic GVHD"],"prefix":"10.1016","volume":"64","author":[{"given":"Asli Odabasi","family":"Giden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"Erkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ipek Yonal","family":"Hindilerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emine","family":"Hidayet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhami","family":"Berber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarik Onur","family":"Tiryaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugba","family":"Zorlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinem","family":"Namdaroglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Sarici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra","family":"Yildizhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muruvvet Seda","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdal","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turgay","family":"Ulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.transci.2024.104053_bib1","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1038\/s41598-021-88080-3","article-title":"Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia","volume":"11","author":"Zhang","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.transci.2024.104053_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","article-title":"The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology","volume":"11","author":"Xu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.transci.2024.104053_bib3","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2024.104053_bib4","article-title":"Efficiency and toxicity of ruxolitinib as a salvage treatment for steroid-refractory chronic graft-versus-host disease","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.transci.2024.104053_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41409-024-02252-z","article-title":"Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis","volume":"59","author":"Baccelli","year":"2024","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2024.104053_bib6","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2024.104053_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2024.104053_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720914489","article-title":"Insights into the role of the JAK\/STAT signaling pathway in graft-versus-host disease","volume":"11","author":"Abboud","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1016\/j.transci.2024.104053_bib9","doi-asserted-by":"crossref","first-page":"8348","DOI":"10.1038\/s41598-022-12407-x","article-title":"Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib","volume":"12","author":"Rodr\u00edguez-Gil","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.transci.2024.104053_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109799","article-title":"Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect","volume":"9","author":"Choi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.transci.2024.104053_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"10.1016\/j.transci.2024.104053_bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtct.2021.10.015","article-title":"Efficacy and safety of ruxolitinib in steroid-refractory\/dependent chronic graft-versus-host disease: real-world data and challenges","volume":"28","author":"Redondo","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.transci.2024.104053_bib13","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/bmt.2016.256","article-title":"Ruxolitinib treatment for GvHD in patients with myelofibrosis","volume":"51","author":"Mori","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2024.104053_bib14","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.transci.2024.104053_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41409-019-0731-x","article-title":"Grupo Espa\u00f1ol de Trasplante Hematopoy\u00e9tico (GETH). Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study","volume":"55","author":"G\u00f3mez","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2024.104053_bib16","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.transci.2024.104053_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2024.104053_bib18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ajh.25898","article-title":"Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: results of a multi-center prospective study","volume":"95","author":"Zhao","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.transci.2024.104053_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.34750","article-title":"Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation","volume":"4","author":"Wu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.transci.2024.104053_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/JVI.01571-06","article-title":"Inhibitory effect of gamma interferon on BK virus gene expression and replication","volume":"81","author":"Abend","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.transci.2024.104053_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-137694","article-title":"Ruxolitinib (RUX) vs best available therapy (BAT) in patients with steroid-refractory\/steroid-dependent chronic graft-vs-host disease (cGVHD): primary findings from the phase 3, randomized REACH3 study","volume":"136","author":"Zeiser","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.transci.2024.104053_bib22","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s00277-024-05697-w","article-title":"Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis","volume":"103","author":"Denk","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transci.2024.104053_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ejh.13230","article-title":"Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants","volume":"102","author":"Prem","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transci.2024.104053_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.retram.2019.01.001","article-title":"HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant","volume":"67","author":"Ghobadi","year":"2019","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.transci.2024.104053_bib25","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41409-020-0834-4","article-title":"Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults","volume":"55","author":"Moiseev","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2024.104053_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/08880018.2020.1868637","article-title":"Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity","volume":"38","author":"Mozo","year":"2021","journal-title":"Pedia Hematol Oncol"},{"key":"10.1016\/j.transci.2024.104053_bib27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.25376","article-title":"Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results","volume":"94","author":"Gonz\u00e1lez Vicent","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2024.104053_bib28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41409-019-0731-x","article-title":"Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study","volume":"55","author":"Escamilla G\u00f3mez","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2024.104053_bib29","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2017.03.029","article-title":"Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients","volume":"23","author":"Khandelwal","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2024.104053_bib30","doi-asserted-by":"crossref","first-page":"120.e1","DOI":"10.1016\/j.jtct.2022.11.025","article-title":"A multicenter, retrospective study evaluating clinical outcomes of ruxolitinib therapy in heavily pretreated chronic GVHD patients with steroid failure","volume":"29","author":"White","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.transci.2024.104053_bib31","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2012-11-465583","article-title":"Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease","volume":"121","author":"Inamoto","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.transci.2024.104053_bib32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.transci.2024.104053_bib33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3324\/haematol.2014.117283","article-title":"Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease","volume":"100","author":"Palmer","year":"2015","journal-title":"Haematologica"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224002349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224002349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T08:48:24Z","timestamp":1738572504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050224002349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1473050224002349"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2024.104053","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Ruxolitinib in the management of chronic GVHD","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2024.104053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104053"}}